CoChat

Role of PPAR-γ Agonist Thiazolidinediones in Treatment of Pre-Diabetic and Diabetic Individuals: A Cardiovascular Perspective

Dumasia, Rupal, Eagle, Kim, Kline-Rogers, Eva, May, Niquole, Cho, Leslie, Mukherjee, Debabrata · 2005 · Current Drug Target -Cardiovascular & Hematological Disorders

The DOI matches its Crossref record.

Abstract

The peroxisome proliferator-activated receptors (PPARs) are nuclear fatty acid receptors, which contain a type II zinc finger DNA binding motif and a hydrophobic ligand binding pocket. These receptors are thought to play an important role in metabolic diseases such as obesity, insulin resistance, and coronary artery disease. Three subtypes of PPAR receptors have been described: PPARalpha, PPARdelta/beta, and PPARgamma. PPARalpha is found in the liver, muscle, kidney, and heart. In the liver, its role is to up-regulate genes involved in fatty acid uptake (beta-oxidation and omega-oxidation). PPARdelta/beta is involved in fatty acid oxidation in muscle. PPARgamma has high expression in fat, low expression in the liver, and very low expression in the muscle. The thiazolidinediones (TZD) are synthetic ligands of PPARgamma. By activating a number of genes in tissues, PPARgamma increases glucose and lipid uptake, increases glucose oxidation, decreases free fatty acid concentration, and decreases insulin resistance. There is a sound rationale for the use of TZDs in patients with type 2 diabetes mellitus and promising preliminary data in patients with patients with pre-diabetes. In patients with type 2 diabetes, thiazolidinediones had been shown to decrease mean HbA(1c)by 1.5% and lower HbA(1c) to less than 7% in 30% of patients. Decreased muscle insulin resistance primarily mediates the glucose lowering effect. In addition, there are several nonhypoglycemic effects of TZDs which may be beneficial to both diabetics and patients with pre-diabetes. These include effects on lipid metabolism, blood pressure, endothelial function, atherosclerotic plaque, coagulation, and albuminuria. In a pilot study, we recently demonstrated that insulin sensitizers such as thiazolidinediones appear to be associated with better clinical outcomes compared to insulin providers in diabetic patients presenting with acute coronary syndromes. In another study, we showed that the prediabetic state is a marker for worse prognosis in patients with acute coronary syndromes. In this article, we review the existing literature on the effectiveness of PPAR-gamma agonists in patients with either overt diabetes or a prediabetic state.

Overview

Integrity signals

Registry

Crossref · 10.2174/156800605774370362

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 56

Metadata

Authors
Dumasia, R., Eagle, K., Kline-Rogers, E., May, N., Cho, L., & Mukherjee, D.
Affiliations
  • University of Michigan (US)
  • Cleveland Clinic (US)
  • University of Kentucky (US)
Venue
Current Drug Target -Cardiovascular & Hematological Disorders
Published
2005-10-01
Volume
5
Issue
5
Pages
377-386
ISSN
1568-0061 (ISSN-L)
OpenAlex
W2050158436
Cited by
56
References
0
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 1 · 2018: 5 · 2017: 2 · 2016: 5 · 2014: 6 · 2013: 1 · 2012: 1
FWCI
1.63
Type
journal article
Language
en
Open access
closed
Locations
  • Cardiovascular & Haematological Disorders - Drug Targets (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
thiazolidinediones, PPARγ agonists, type 2 diabetes, prediabetes, insulin resistance, insulin sensitizers, acute coronary syndrome, cardiovascular risk, endothelial function, atherosclerosis, albuminuria, HbA1c, lipid metabolism, blood pressure
MeSH terms
Diabetes Mellitus, Type 2, Humans, Prediabetic State, Thiazoles, Thiazolidinediones, PPAR gamma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of PPAR-γ Agonist Thiazolidinediones in Treatment of Pre-Diabetic and Diabetic Individuals: A Cardiovascular Perspective. https://app.cochat.ai/papers/10.2174/156800605774370362
The paper
Dumasia, R., Eagle, K., Kline-Rogers, E., May, N., Cho, L., & Mukherjee, D. (2005). Role of PPAR-γ Agonist Thiazolidinediones in Treatment of Pre-Diabetic and Diabetic Individuals: A Cardiovascular Perspective. Current Drug Target -Cardiovascular & Hematological Disorders. https://doi.org/10.2174/156800605774370362

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.